[1]王 玉,马依晨,李 艳,等.双嘧达莫治疗川崎病临床疗效及对患儿CRP、PCT等水平影响研究*[J].陕西医学杂志,2018,(12):1644-1647.
　Wang Yu,Ma Yichen,Li Yan,et al.Dipyridamole promotes the improvement of CRP, PCT and other inflammatory mediators in children with Kawasaki disease[J].,2018,(12):1644-1647.
点击复制

双嘧达莫治疗川崎病临床疗效及对患儿CRP、PCT等水平影响研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2018年12期
页码:
1644-1647
栏目:
药物与临床
出版日期:
2018-12-31

文章信息/Info

Title:
Dipyridamole promotes the improvement of CRP, PCT and other inflammatory mediators in children with Kawasaki disease
文章编号:
DOI:10.3969/j.issn.1000-7377.2018.12.037
作者:
王 玉; 马依晨; 李 艳; 马红茹△
陕西省宝鸡市中心医院儿科（宝鸡721000）
Author(s):
Wang Yu;  Ma Yichen;  Li Yan;  et al.
Department of Pediatrics, Baoji Central Hospital in Shaanxi Province(Baoji 721000)
关键词:
粘膜皮肤淋巴结综合证/药物疗法 抗血小板聚集药/治疗应用 C反应蛋白质/代谢 降钙素原/代谢
Keywords:
Key words Mucocutaneous lymph node syndrome/drug therapy Platelet aggregation inhibitors/therapeutic/uses C-reactive protein/metabolism Procalcitonin/metabolism
分类号:
R725.9
文献标志码:
A
摘要:
摘 要 目的：探讨双嘧达莫治疗川崎病的疗效及其对患儿CRP、PCT等的影响。方法：将86例川崎病患儿随机分成观察组和对照组各43例。对照组患儿以阿司匹林联合丙种球蛋白治疗，观察组患儿则在对照组基础上以双嘧达莫治疗。对两组患儿的临床治疗效果，临床症状缓解情况，CRP、PCT及相关的变化情况以及安全性进行比较、分析。结果：观察组治疗的总有效率为95.3%，明显高于对照组81.4%（P<0.05）；观察组的临床症状缓解时间明显短于对照组（P<0.05）；两组的CRP、PCT水平均较治疗前显著改善，且观察组改善的更为显著（P<0.05）；两组在不良反应方面比较的差异无统计学意义（P>0.05）。结论：双嘧达莫应用于川崎病治疗中的效果显著，有助于患者炎性反应的控制，临床症状的改善，且不会增加治疗的风险，具有积极的临床意义。
Abstract:
Abstract Objective: To investigate the effects of dipyridamole on Kawasaki disease and its effects on CRP, PCT and other inflammatory mediators.Methods: 86 children with Kawasaki disease were divided into the observation group (43 cases) and control group (43 cases). The patients of control group were treated with aspirin and gamma globulin. Based on control group, the patients of observation group were treated with dipyridamole. BPRS score, MCCB score and TESS score were used to evaluate the effect, cognitive function and safety of the patients of two groups. The clinical treatment effect, the relief of clinical symptoms, changes of CRP, PCT and related inflammatory mediators and safety of two groups were compared and analyzed.Results: The total effective rate of observation group was 95.3%, which was significantly higher than 81.4% of the control group (P<0.05). Clinical symptoms remission time of observation group were significantly shorter than that of the control group (P<0.05). The CRP and PCT levels in both groups were all significantly improved than before, and the observation group improved more significantly (P< 0.05). The levels of inflammatory mediators in both groups were all significantly improved than before, and the observation group improved more significantly (P< 0.05). There was no significant difference in adverse reactions between the two groups (P > 0.05). Conclusion: The efficacy of dipyridamole in the treatment of Kawasaki disease is significant, which contributes to the control of inflammatory reactions and the improvement of clinical symptoms. And it does not increase the risk of treatment, which makes it have a positive clinical significance.

参考文献/References:


[1] 朱 迪,罗 钢.不完全川崎病患儿的实验室检查分析[J].中国医科大学学报,2017,46(3):219-222.
[2] 梁妍琰,张晓梅,朱 华,等.不同年龄谱的川崎病患儿90例临床特征研究[J].中国小儿急救医学,2017,24(3):235-238.
[3] 邹 娜. 双嘧达莫辅助丙种球蛋白及阿司匹林治疗川崎病对患儿抗血小板聚集因子及疗效影响研究[J]. 陕西医学杂志,2018,47(1):102-104.
[4] 王朝辉.小儿川崎病应用丙种球蛋白治疗的效果评估及最佳剂量研究[J].检验医学与临床,2017,14(4):531-532,535.
[5] Japan Kawasaki Disease Research Committee (1984) diagnostic guide lines of Kawasaki disease, 4th rev. ed[M]. Tokyo, 1984:25.
[6] 杨林军,蒲 燕,平 虎,等.注射用血塞通联合双嘧达莫治疗冠心病心绞痛疗效观察及对患者免疫功能影响的研究[J].安徽医药,2017,21(11):2081-2084.
[7] Amer K A, Hurren J R, Edwin S B, et al. Regadenoson versus dipyridamole: A comparison of the frequency of adverse events in patients undergoing myocardial perfusion imaging[J]. Pharmacotherapy, 2017, 37(6):657-661.
[8] 种 莉,陈 丽,唐 鹏,等.阿司匹林肠溶片与双嘧达莫联合用于脑血栓治疗的临床分析及对NIHSS评分的影响[J].河北医学,2017,23(8):1392-1395.
[9] Piovesana P, Offelli P, D'Ambrosio F, et al. Addition of exercise to dipyridamole stress echocardiography in order to carry on the ischemic cascade: Role in the diagnosis of coronary artery disease and prognostic value[J]. J Cardiovasc Echogr, 2016, 26(4):115-119.〖ZK)〗
[10] 刘 杰. 解毒化瘀汤联合丙种球蛋白治疗川崎病临床观察[J]. 陕西中医,2017,38(2):180-181.
[11] 张清秀,吕志勇,李启亮,等.降钙素原和D-二聚体等联合检测对儿童川崎病早期诊断的应用价值[J].临床和实验医学杂志,2017,16(20):2060-2063.
[12] 钟威达,陈元花,龙 新,等.CRP、TNF-α及IgG在川崎病患儿中的变化及其意义[J].海南医学,2017,28(2):240-242.
[13] Hu P, Jiang GM, Wu Y, et al. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease[J]. Clin Chim Acta, 2017, 471:76-80.
[14] 张晓燕,吴守振,刘春风,等.川崎病患者糖皮质激素受体、IL-17A、IL-6检测的临床意义[J].陕西医学杂志,2016,45(10):1392-1393,1421.
[15] 王春岩,白艳辉,宫奇莲,等.川崎病患儿血清HMGB1、MIF水平的表达及临床意义[J].中国医师杂志,2016,18(8):1247-1249.

备注/Memo

备注/Memo:
*陕西省自然科学基金资助项目(2016JM8061)
更新日期/Last Update: 2019-01-21